Pages that link to "Q35065913"
Jump to navigation
Jump to search
The following pages link to Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy (Q35065913):
Displaying 50 items.
- Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice (Q24299595) (← links)
- Long-term safety and efficacy of enzyme replacement therapy for Fabry disease (Q24533551) (← links)
- Electrocardiographic Changes and Arrhythmia in Fabry Disease (Q26751508) (← links)
- Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders (Q26771677) (← links)
- Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis (Q26864740) (← links)
- Agalsidase alfa: a review of its use in the management of Fabry disease (Q28274194) (← links)
- Glycosphingolipidoses: beyond the enzymatic defect (Q28290521) (← links)
- A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy (Q28478586) (← links)
- Temporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in fabry disease? (Q30458149) (← links)
- Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data (Q30578294) (← links)
- Skin-impedance in Fabry Disease: a prospective, controlled, non-randomized clinical study (Q30850675) (← links)
- [Neurological aspects of Fabry's disease]. (Q31041350) (← links)
- Neurological presentations of lysosomal diseases in adult patients (Q31137458) (← links)
- Kidney transplantation improves survival and is indicated in Fabry's disease (Q33230606) (← links)
- Corrective effect on Fabry mice of yeast recombinant human alpha-galactosidase with N-linked sugar chains suitable for lysosomal delivery (Q33236195) (← links)
- Imaging mass spectrometry: a new tool for the analysis of skin biopsy. Application in Fabry's disease (Q33263196) (← links)
- Systemic inflammatory diseases (SIDS), what's in a name (Q33282437) (← links)
- Angiokeratomas of Fabry successfully treated with intense pulsed light (Q33373387) (← links)
- Atmospheric pressure photoionization coupled to porous graphitic carbon liquid chromatography for the analysis of globotriaosylceramides. Application to Fabry disease (Q33434295) (← links)
- The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat (Q33567658) (← links)
- Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34 Cells for Correction of Fabry Disease (Q33752595) (← links)
- Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy (Q33847189) (← links)
- Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. (Q33886219) (← links)
- Multi-system disorders of glycosphingolipid and ganglioside metabolism (Q33902037) (← links)
- Myocardial fibrosis as the first sign of cardiac involvement in a male patient with Fabry disease: report of a clinical case and discussion on the utility of the magnetic resonance in Fabry pathology (Q33936963) (← links)
- Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity (Q34030488) (← links)
- Stroke and Fabry disease. (Q34061632) (← links)
- Excessive Daytime Sleepiness Is a Common Symptom in Fabry Disease (Q34131397) (← links)
- Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease (Q34257466) (← links)
- Depletion of globosides and isoglobosides fully reverts the morphologic phenotype of Fabry disease (Q34294988) (← links)
- Fabry disease - current treatment and new drug development (Q34368512) (← links)
- Serum Globotriaosylceramide Assay as a Screening Test for Fabry Disease in Patients with ESRD on Maintenance Dialysis in Korea (Q34385057) (← links)
- Antiepileptic medications increase osteoporosis risk in male fabry patients: bone mineral density in an Australian cohort. (Q34560222) (← links)
- Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. (Q34595095) (← links)
- Cryptogenic stroke and small fiber neuropathy of unknown etiology in patients with alpha-galactosidase A -10T genotype. (Q34632438) (← links)
- High incidence of later-onset fabry disease revealed by newborn screening (Q34658483) (← links)
- Update on role of agalsidase alfa in management of Fabry disease (Q34883178) (← links)
- Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy (Q34945403) (← links)
- Hypertension in adult Fabry's disease: is cardiotrophin-1 a diagnostic biomarker? (Q34976618) (← links)
- Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936 919G>A (IVS4 919G>A). (Q34993215) (← links)
- Hypertrophic cardiomyopathy: a review (Q35024040) (← links)
- Carboxyl-terminal truncations alter the activity of the human α-galactosidase A (Q35125851) (← links)
- Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. (Q35247511) (← links)
- Fabry disease in the era of enzyme replacement therapy: a renal perspective (Q35738491) (← links)
- Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the α-galactosidase A (GLA) gene. (Q35763202) (← links)
- Eight-Year Follow-Up of Neuropsychiatric Symptoms and Brain Structural Changes in Fabry Disease (Q35764867) (← links)
- The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy. (Q35775374) (← links)
- Enzyme replacement and enhancement therapies for lysosomal diseases (Q35800534) (← links)
- Genetics of cerebrovascular disorders (Q36018306) (← links)
- Evaluation of oxidative stress markers and cardiovascular risk factors in Fabry Disease patients (Q36075584) (← links)